Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuya Mitsudomi

Showing results (51-60 of 336) with videos related to

Pageof 34
Sort By:
The Journal of Pathology|May 14, 2004
CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomasYasushi Yatabe, Takaomi Koga, Tetsuya Mitsudomi, et al.
Therapeutic Advances in Medical Oncology|July 27, 2011
The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutationsIsamu Okamoto, Tetsuya Mitsudomi, Kazuhiko Nakagawa, et al.
International Journal of Clinical Oncology|June 10, 2011
Lung cancers unrelated to smoking: characterized by single oncogene addiction?Kenichi Suda, Kenji Tomizawa, Yasushi Yatabe, et al.
Cancer Metastasis Reviews|June 28, 2012
Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destinyKenichi Suda, Hiroshi Mizuuchi, Yoshihiko Maehara, et al.
Annals of Thoracic and Cardiovascular Surgery : Official Journal of the Association of Thoracic and Cardiovascular Surgeons of Asia|September 16, 2006
Clinical aspects of multimodality therapy for resectable locoregional esophageal cancerMasayuki Shinoda, Shunzo Hatooka, Shoichi Mori, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2008
EGFR T790M mutation: a double role in lung cancer cell survival?Kenichi Suda, Ryoichi Onozato, Yasushi Yatabe, et al.
The American Journal of Surgical Pathology|April 16, 2005
EGFR mutation is specific for terminal respiratory unit type adenocarcinomaYasushi Yatabe, Takayuki Kosaka, Takashi Takahashi, et al.
Lung Cancer (Amsterdam, Netherlands)|June 17, 2022
Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapiesMelissa Johnson, Marina Chiara Garassino, Tony Mok, et al.
Clinical Orthopaedics and Related Research|January 16, 2008
Predictors of survival in patients with bone metastasis of lung cancerHideshi Sugiura, Kenji Yamada, Takahiko Sugiura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2010
Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancerAtsuko Kitamura, Waki Hosoda, Eiichi Sasaki, et al.
Pageof 34

Showing results (51-60 of 336) with videos related to

Sort By:
Pageof 34
The Journal of Pathology|May 14, 2004
CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomasYasushi Yatabe, Takaomi Koga, Tetsuya Mitsudomi, et al.
Therapeutic Advances in Medical Oncology|July 27, 2011
The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutationsIsamu Okamoto, Tetsuya Mitsudomi, Kazuhiko Nakagawa, et al.
International Journal of Clinical Oncology|June 10, 2011
Lung cancers unrelated to smoking: characterized by single oncogene addiction?Kenichi Suda, Kenji Tomizawa, Yasushi Yatabe, et al.
Cancer Metastasis Reviews|June 28, 2012
Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destinyKenichi Suda, Hiroshi Mizuuchi, Yoshihiko Maehara, et al.
Annals of Thoracic and Cardiovascular Surgery : Official Journal of the Association of Thoracic and Cardiovascular Surgeons of Asia|September 16, 2006
Clinical aspects of multimodality therapy for resectable locoregional esophageal cancerMasayuki Shinoda, Shunzo Hatooka, Shoichi Mori, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 20, 2008
EGFR T790M mutation: a double role in lung cancer cell survival?Kenichi Suda, Ryoichi Onozato, Yasushi Yatabe, et al.
The American Journal of Surgical Pathology|April 16, 2005
EGFR mutation is specific for terminal respiratory unit type adenocarcinomaYasushi Yatabe, Takayuki Kosaka, Takashi Takahashi, et al.
Lung Cancer (Amsterdam, Netherlands)|June 17, 2022
Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapiesMelissa Johnson, Marina Chiara Garassino, Tony Mok, et al.
Clinical Orthopaedics and Related Research|January 16, 2008
Predictors of survival in patients with bone metastasis of lung cancerHideshi Sugiura, Kenji Yamada, Takahiko Sugiura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2010
Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancerAtsuko Kitamura, Waki Hosoda, Eiichi Sasaki, et al.
Pageof 34